Efficacy and Safety of Insulin Degludec versus Insulin Glargine: A Systematic Review and Meta-Analysis of Fifteen Clinical Trials
Table 2
Summary of the main results.
Population
N1
T1DM: pooled effect size IDeg : IGlar (95% confidence interval)
N2
T2DM: pooled effect size IDeg : IGlar (95% confidence interval)
N (N1 + N2)
Overall: pooled effect size IDeg : IGlar (95% confidence interval)
Items
Change of HbA1c
2342
MD = 0.05% (−0.01%, 0.10%)
13,986
MD = 0.04% (0.00, 0.07%)
16,328
MD = 0.04% (0.01%, 0.07%)
Change of FPG
2302
MD = −0.84 (−1.18, −0.51)
12,544
MD = −0.34 (−0.45, −0.23)
14,846
MD = −0.41 (−0.54, −0.28)
Change of body weight
2342
MD = −0.04 (−0.35, 0.26)
13,986
MD = 0.05 (−0.11, 0.22)
16,328
MD = 0.03 (−0.11, 0.18)
Participants achieved HbA1c levels of <7%
629
RR = 0.93, (0.75, 1.15)
4754
RR = 0.96, (0.90, 1.03)
5383
RR = 0.96, (0.90, 1.02)
Overall hypoglycemia
2302
RR = 0.97 (0.87, 1.08)
6349
RR = 0.82 (0.73, 0.92)
8651
RR = 0.88 (0.81, 0.96)
Nocturnal hypoglycemia
2302
RR = 0.74 (0.68, 0.81)
6349
RR = 0.74 (0.66, 0.82)
8651
RR = 0.74 (0.69, 0.79)
Adverse events
2036
OR = 0.96 (0.78, 1.19)
13,590
OR = 0.94 (0.87, 1.01)
15,626
OR = 0.94 (0.88, 1.01)
Serious adverse events
2214
OR = 0.89 (0.67, 1.18)
13,590
OR = 0.95, (0.87, 1.03)
15,804
OR = 0.95 (0.87, 1.02)
Adverse events possibly/probably related to the trial product
2036
OR = 1.24 (0.93, 1.64)
5496
OR = 1.05 (0.86, 1.29)
7532
OR = 1.11 (0.94, 1.31)
IDeg: insulin degludec; IGlar: insulin glargine; N1: number of patients with T1DM; N2: number of patients with T2DM; N: number of patients; T1DM: type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus; MD: mean difference; RR: risk ratio; OR: odds ratio. .
